ERJENZ

Allergan Sales, Llc

Application Filed: 2015-04-01

Trademark Application Details

Status

602

Dead/Abandoned

ABANDONED-FAILURE TO RESPOND OR LATE RESPONSE

Research	OneLook Acronym Finder
Serial Number	86583902
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Attorney Name	Matthew O. Brady
Law Office Assigned	M30
Employee Name	DICKEY, ERICA G.J.

Timeline

2015-04-01	Application Filed
2017-01-09	Abandon
2017-02-03	Location: TMO LAW OFFICE 112 - EXAMINING ATTORNEY ASSIGNED
2017-02-03	Status: Dead/Abandoned
2018-07-08	Transaction Date

Trademark Applicants & Owners

Owner:	ALLERGAN SALES, LLC
Address	5 GIRALDA FARMS MADISON DE 07940
Legal Entity Type	Limited Liability Company
Legal Entity State	DE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

MATTHEW O. BRADY
Actavis Inc
400 Interpace Pkwy
Parsippany, NJ 07054-1120

Good, Services, and Codes

International Codes:	5
U.S. Codes:	006,018,044,046,051,052

Type Code	Type
GS0051	Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting the sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting the urogenital organs; Pharmaceuticals and medicines affecting the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Type Code

Type

GS0051

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting the sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting the urogenital organs; Pharmaceuticals and medicines affecting the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Trademark Filing History

Description	Date	Event Coding
NEW APPLICATION ENTERED IN TRAM	2015-04-04	1 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	2015-04-10	2 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER	2015-06-04	3 DOCK D:Assigned to Examiner
NON-FINAL ACTION WRITTEN	2015-06-10	4 CNRT R:Renewal
NON-FINAL ACTION E-MAILED	2015-06-10	5 GNRT F:First Action
NOTIFICATION OF NON-FINAL ACTION E-MAILED	2015-06-10	6 GNRN O:Outgoing Correspondence
TEAS RESPONSE TO OFFICE ACTION RECEIVED	2015-12-03	7 TROA I:Incoming Correspondence
CORRESPONDENCE RECEIVED IN LAW OFFICE	2015-12-03	8 CRFA I:Incoming Correspondence
TEAS/EMAIL CORRESPONDENCE ENTERED	2015-12-03	9 TEME I:Incoming Correspondence
SUSPENSION LETTER WRITTEN	2015-12-08	10 CNSL R:Renewal
LETTER OF SUSPENSION E-MAILED	2015-12-08	11 GNSL S:
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED	2015-12-08	12 GNS3 O:Outgoing Correspondence
ASSIGNED TO LIE	2016-06-23	13 ALIE A:Allowance for Publication
LIE CHECKED SUSP - TO ATTY FOR ACTION	2016-06-24	14 RCCK S:
NON-FINAL ACTION WRITTEN	2016-07-06	15 CNRT R:Renewal
NON-FINAL ACTION E-MAILED	2016-07-06	16 GNRT O:Outgoing Correspondence
NOTIFICATION OF NON-FINAL ACTION E-MAILED	2016-07-06	17 GNRN O:Outgoing Correspondence
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE	2017-02-03	18 ABN2 O:Outgoing Correspondence
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND	2017-02-03	19 MAB2 O:Outgoing Correspondence
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP	2018-01-03	20 ASGN I:Incoming Correspondence

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.